Published in Clin Vaccine Immunol on January 01, 2006
Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies. Arthritis Res Ther (2008) 1.47
A Systematic Review of Peripheral and Central Nervous System Involvement of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome, and Associated Immunological Profiles. Int J Chronic Dis (2015) 1.42
Ribosomal P autoantibodies are present before SLE onset and are directed against non-C-terminal peptides. J Mol Med (Berl) (2010) 0.97
Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profile. BMC Med (2013) 0.83
Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis. World J Hepatol (2014) 0.77
Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope. Rheumatol Int (2010) 0.76
Antibodies directed against ribosomal P proteins cross-react with phospholipids. Clin Exp Immunol (2007) 0.76
Anti-ribosomal-P antibodies in lupus nephritis, neuropsychiatric lupus, lupus hepatitis, and Chagas' disease: promising yet limited in clinical utility. Rheumatol Int (2014) 0.75
Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus. Arthritis Res Ther (2011) 0.75
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 67.54
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum (1999) 7.30
Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum (1995) 2.67
Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med (1987) 2.47
Lupus autoantibodies target ribosomal P proteins. J Exp Med (1985) 2.28
Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) (2002) 1.61
Clinical and serologic associations of the antiribosomal P protein antibody. Arthritis Rheum (1986) 1.58
Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med (1991) 1.51
Autoantibodies in neuropsychiatric lupus. Autoimmunity (2002) 1.36
Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum (1998) 1.26
Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis Rheum (1996) 1.23
Autoantibodies against ribosomal proteins found with high frequency in patients with systemic lupus erythematosus with active disease. J Rheumatol (1991) 1.16
Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins. J Mol Med (Berl) (2003) 1.04
Studies on the specificity and clinical correlation of antiribosomal antibodies in systemic lupus erythematosus sera. Arthritis Rheum (1979) 1.01
Autoantibodies directed against ribosomal P proteins: use of a multiple antigen peptide as the coating agent in ELISA. J Immunol Methods (1995) 0.97
Long-term follow-up of autoantibody profiles in black female lupus patients and clinical comparison with Caucasian and Asian patients. Br J Rheumatol (1997) 0.97
Ribosomal proteins P0, P1, and P2 are phosphorylated by casein kinase II at their conserved carboxyl termini. J Biol Chem (1991) 0.96
Technical and clinical evaluation of anti-ribosomal P protein immunoassays. J Clin Lab Anal (2004) 0.93
Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus. Ann Rheum Dis (1992) 0.93
Antiribosomal P protein antibodies in different populations of patients with systemic lupus erythematosus. Br J Rheumatol (1993) 0.92
Anti-ribosomal P protein antibodies. Autoimmunity (2005) 0.92
The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease. Ann Rheum Dis (2000) 0.91
Prevalence of autoantibodies to ribosomal P proteins in juvenile-onset systemic lupus erythematosus compared with the adult disease. Arthritis Rheum (1999) 0.90
Fluctuations of antibody to ribosomal P proteins correlate with appearance and remission of nephritis in SLE. Lupus (1996) 0.89
Anti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodies. Ann Rheum Dis (2000) 0.89
Ribosomal P antibodies and CNS lupus. Lupus (2003) 0.87
Heterogeneity of anti-dsDNA antibodies in their cross-reaction with ribosomal P protein. J Autoimmun (1999) 0.85
Diagnostic tests for antiribosomal p protein antibodies: a comparative evaluation of immunoblotting and ELISA assays. J Autoimmun (2002) 0.84
The effect of phosphorylation and site-specific mutations in the immunodominant epitope of the human ribosomal P proteins. Clin Immunol Immunopathol (1994) 0.84
Anti-dsDNA autoantibody cross-reacts with the C-terminal hydrophobic cluster region containing phenylalanines in the acidic ribosomal phosphoprotein P1 to exert a cytostatic effect on the cells. Biochem Biophys Res Commun (1999) 0.82
Major immunoreactive domains of human ribosomal P proteins lie N-terminal to a homologous C-22 sequence: application to a novel ELISA for systemic lupus erythematosus. Clin Exp Immunol (2005) 0.82
Anti-ribosomal antibodies from lupus patients bind DNA. Clin Exp Immunol (2002) 0.82
Evidence for the participation of anti-ribosomal P antibodies in lupus nephritis. Arthritis Rheum (1999) 0.82
Autoantibodies directed against the ribosomal P proteins are not only directed against a common epitope of the P0, P1 and P2 proteins. J Autoimmun (1999) 0.82
Evaluation of assays for the detection of autoantibodies to the ribosomal P proteins. Clin Immunol (2000) 0.80
Quantification of antiribosomal P0 protein antibodies by ELISA with recombinant P0 fusion protein and their association with central nervous system disease in systemic lupus erythematosus. J Rheumatol (1995) 0.79
Antibodies to ribosomal P proteins and hepatic damage in undifferentiated CTD. Ann Rheum Dis (1996) 0.79
Lifeact: a versatile marker to visualize F-actin. Nat Methods (2008) 12.23
Stress granules and processing bodies are dynamically linked sites of mRNP remodeling. J Cell Biol (2005) 9.25
Prevalence of Celiac disease among children in Finland. N Engl J Med (2003) 7.27
Disruption of GW bodies impairs mammalian RNA interference. Nat Cell Biol (2005) 5.52
A phosphorylated cytoplasmic autoantigen, GW182, associates with a unique population of human mRNAs within novel cytoplasmic speckles. Mol Biol Cell (2002) 5.34
Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol (2006) 5.22
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12
The GW182 protein colocalizes with mRNA degradation associated proteins hDcp1 and hLSm4 in cytoplasmic GW bodies. RNA (2003) 4.40
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis (2013) 3.99
Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol (2013) 3.42
GW182 is critical for the stability of GW bodies expressed during the cell cycle and cell proliferation. J Cell Sci (2004) 3.31
Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum (2002) 3.30
Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum (2004) 3.23
Maintenance of serum antibody levels. Annu Rev Immunol (2005) 3.20
Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood (2004) 3.17
Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest (2012) 3.09
Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev (2013) 2.87
Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med (2004) 2.85
HIV and autoimmunity. Autoimmun Rev (2002) 2.83
Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis (2007) 2.76
Measurement of electrical skin impedance of dermal-visceral zones as a diagnostic tool for inner organ pathologies: a blinded preliminary evaluation of a new technique. Isr Med Assoc J (2005) 2.57
Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun (2009) 2.49
Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol (2012) 2.43
Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev (2010) 2.38
B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum (2009) 2.26
Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther (2006) 2.18
Vaccination may be associated with autoimmune diseases. Isr Med Assoc J (2004) 2.14
Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J Rheumatol (2012) 2.12
The influence of pregnancy on the development of autoimmunity in chronic lymphocytic leukemia. Leuk Lymphoma (2006) 2.07
The Lancet against Israel. Isr Med Assoc J (2013) 2.03
Intensive lipid-lowering therapy: obvious benefits, possible risks. Isr Med Assoc J (2006) 2.02
Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum (2008) 2.00
Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol (2014) 1.99
Memory B and memory plasma cells. Immunol Rev (2010) 1.95
Formation of GW bodies is a consequence of microRNA genesis. EMBO Rep (2006) 1.92
Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood (2008) 1.91
Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis (2009) 1.84
Small interfering RNA-mediated silencing induces target-dependent assembly of GW/P bodies. Mol Biol Cell (2007) 1.83
The role of inflammatory cytokines in the pathogenesis of systemic lupus erythematosus-related atherosclerosis: a novel target for treatment? J Rheumatol (2006) 1.79
Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun (2009) 1.78
Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther (2006) 1.78
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum (2004) 1.75
Plasma cell differentiation and survival. Curr Opin Immunol (2008) 1.71
Association between vaccination and Guillain-Barré syndrome. Lancet Infect Dis (2013) 1.69
The C-terminal half of human Ago2 binds to multiple GW-rich regions of GW182 and requires GW182 to mediate silencing. RNA (2009) 1.69
Vitamin D insufficiency in a sunny environment: a demographic and seasonal analysis. Isr Med Assoc J (2010) 1.68
Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun (2010) 1.67
Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol (2006) 1.66
Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol (2007) 1.64
The role of GW/P-bodies in RNA processing and silencing. J Cell Sci (2007) 1.63
Humoral immunity and long-lived plasma cells. Curr Opin Immunol (2002) 1.63
Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc Natl Acad Sci U S A (2010) 1.63
Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol (2011) 1.62
Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum (2006) 1.62
Increasing incidence of diabetes after gestational diabetes: a long-term follow-up in a Danish population. Diabetes Care (2004) 1.61
Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol (2003) 1.61
Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmun Rev (2012) 1.60
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum (2012) 1.59
The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev (2009) 1.57
The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum (2009) 1.57
The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med (2013) 1.56
Helicobacter pylori serology in autoimmune diseases - fact or fiction? Clin Chem Lab Med (2013) 1.56
The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity (2004) 1.54
Gender and autoimmunity. Autoimmun Rev (2006) 1.54
Erdheim-Chester Disease: a comprehensive review of the literature. Orphanet J Rare Dis (2013) 1.54
Identification of GW182 and its novel isoform TNGW1 as translational repressors in Ago2-mediated silencing. J Cell Sci (2008) 1.53
Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol (2012) 1.53
Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum (2008) 1.53
Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol (2005) 1.52
Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood (2005) 1.51
Inflammatory bowel disease: adverse effect of isotretinoin. Isr Med Assoc J (2009) 1.51
Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther (2010) 1.50
Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies. Arthritis Res Ther (2008) 1.47
Induction of cytoplasmic rods and rings structures by inhibition of the CTP and GTP synthetic pathway in mammalian cells. PLoS One (2011) 1.47
Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol (2006) 1.46
A new hypothesis of the possible mechanisms of gender differences in systemic lupus erythematosus. Clin Exp Rheumatol (2010) 1.45
Thymoma and autoimmunity. Cell Mol Immunol (2011) 1.44
Novel aspects of Sjögren's syndrome in 2012. BMC Med (2013) 1.44
The association of a nonsynonymous single-nucleotide polymorphism in TNFAIP3 with systemic lupus erythematosus and rheumatoid arthritis in the Japanese population. Arthritis Rheum (2010) 1.43
IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun (2006) 1.43
Intelligent nutrition: health-promoting mechanisms of probiotics. Isr Med Assoc J (2003) 1.42
Polyarticular septic arthritis with bilateral psoas abscesses following acupuncture. Acupunct Med (2009) 1.41
Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther (2007) 1.40
Systemic thromboembolism in inflammatory bowel disease: mechanisms and clinical applications. Ann N Y Acad Sci (2005) 1.39
Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev (2006) 1.39
EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis (2010) 1.38
Hippocrates' Oath is challenged. Isr Med Assoc J (2009) 1.38
Infections and SLE. Autoimmunity (2005) 1.38
CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation (2004) 1.36
Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad Sci (2007) 1.36
Lupus nephritis: a critical review. Autoimmun Rev (2012) 1.36
Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity (2005) 1.36
Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun (2006) 1.35
Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum (2008) 1.35
Parotitis as the presenting symptom of Wegener's granulomatosis: case report and meta-analysis. Isr Med Assoc J (2013) 1.35